Clinical Trial Update: A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) [Phase 1]

View source ↗

Summary

A Phase 1b trial (SHARK) evaluating HC-7366, an ISR agonist, in kidney cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• HC-7366

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Phase 1b, HC-7366 | Phase 1 | Status: RECRUITING